Clone:
REA150
Type of antibody:
Primary antibodies, Recombinant antibodies
Isotype:
recombinant human IgG1
Applications:
FC, MICS, IF, IHC
Alternative names:
SLAMF7, 19A, CRACC, CS1

Extended validation for CD319 (CRACC) Antibody, anti-human, REAfinity™

Specificity

Epitope competition
In order to compare the epitope specificity of an antibody, the clone being used is compared with other known clones recognizing the same antigen in a competition assay.
Other clonesOverlap in epitope recognition with REA150
235614-
162++
162.1++
162(CRACC)++
Cells were incubated with an excess of purified unconjugated CD319 (CRACC) (REA150) antibody followed by staining with fluorochrome-conjugated antibodies of other known clones against the same marker. Based on the fluorescence signal obtained, the clones were identified as recognizing completely overlapping (++), partially overlapping (+), or completely different epitopes (-) of the marker.

Sensitivity

Performance comparison
Selected fluorochrome conjugated antibodies from Miltenyi Biotec were compared to commercially available hybridoma clones in flow cytometry analysis.
View details
Flow cytometric comparison of different clones for CD319 (CRACC). Human peripheral blood mononuclear cells (PBMCs) were stained with CD319 (CRACC) antibodies and with a suitable counterstaining. As a control, CD319 (CRACC) antibody staining was omitted and cells were measured in the same channels. Flow cytometry was performed with the MACSQuant® Analyzer. Cell debris, dead cells, and cell doublets were excluded from the analysis based on scatter signals and 4',6-diamidino-2-phenylindole (DAPI) fluorescence. No FcR Blocking Reagent was used. The recommended titers of respective antibodies from different suppliers were used.
View details
Flow cytometric comparison of different clones for CD319 (CRACC). Human peripheral blood mononuclear cells (PBMCs) were stained with CD319 (CRACC) antibodies and with a suitable counterstaining. As a control, CD319 (CRACC) antibody staining was omitted and cells were measured in the same channels. Flow cytometry was performed with the MACSQuant® Analyzer. Cell debris, dead cells, and cell doublets were excluded from the analysis based on scatter signals and 4',6-diamidino-2-phenylindole (DAPI) fluorescence. No FcR Blocking Reagent was used. The recommended titers of respective antibodies from different suppliers were used.
View details
Flow cytometric comparison of different clones for CD319 (CRACC). Human peripheral blood mononuclear cells (PBMCs) were stained with CD319 (CRACC) antibodies and with a suitable counterstaining. As a control, CD319 (CRACC) antibody staining was omitted and cells were measured in the same channels. Flow cytometry was performed with the MACSQuant® Analyzer. Cell debris, dead cells, and cell doublets were excluded from the analysis based on scatter signals and 4',6-diamidino-2-phenylindole (DAPI) fluorescence. No FcR Blocking Reagent was used. The recommended titers of respective antibodies from different suppliers were used.
Flow cytometric comparison of different clones for CD319 (CRACC). Human peripheral blood mononuclear cells (PBMCs) were stained with CD319 (CRACC) antibodies and with a suitable counterstaining. As a control, CD319 (CRACC) antibody staining was omitted and cells were measured in the same channels. Flow cytometry was performed with the MACSQuant® Analyzer. Cell debris, dead cells, and cell doublets were excluded from the analysis based on scatter signals and 4',6-diamidino-2-phenylindole (DAPI) fluorescence. No FcR Blocking Reagent was used. The recommended titers of respective antibodies from different suppliers were used.
Fixation data
To provide an indication on how an antibody performs after fixation of cells, in-house data on staining results before and after fixation with 3.7% formaldehyde using Miltenyi Biotec antibodies are provided. Different experimental settings may lead to different results.
No fixation
Post fixation
View details
Comparison of staining pattern on non-fixed and fixed cells using CD319 (CRACC) (REA150). The performance of the antibody after fixation was tested by comparing the staining pattern on fresh (no fixation) versus fixed (post fixation) cells.
View details
Comparison of staining pattern on non-fixed and fixed cells using CD319 (CRACC) (REA150). The performance of the antibody after fixation was tested by comparing the staining pattern on fresh (no fixation) versus fixed (post fixation) cells.
Comparison of staining pattern on non-fixed and fixed cells using CD319 (CRACC) (REA150). The performance of the antibody after fixation was tested by comparing the staining pattern on fresh (no fixation) versus fixed (post fixation) cells.

Specifications for CD319 (CRACC) Antibody, anti-human, REAfinity™

Overview

Clone REA150 recognizes CD319, which is a single-pass type I transmembrane protein. CD319 belongs to the SLAM-related receptors (SRRs) family, a subgroup of the CD2 family of Ig-like receptors. Expression of CD319 is found on activated B lymphocytes, natural killer (NK) cells, CD8
+
T lymphocytes, and mature dendritic cells. The cytoplasmic domain of CD319 contains immunoreceptor tyrosine-based switch motifs (ITSMs), which provide the docking sites for recruitment of small SH2-containing adapter proteins, such as SH2D1A/SLAM-associated protein (SAP) and EWS activated transcript 2 (EAT-2). CD319 displays homophilic interaction and is involved in mediating NK cell cytotoxicity, in the absence of an inhibitory receptor engagement.
Additional information: Clone REA150 displays negligible binding to Fc receptors.

Alternative names

SLAMF7, 19A, CRACC, CS1

Detailed product information

Technical specifications

CloneREA150
Clonalitymonoclonal
Isotyperecombinant human IgG1
Isotype controlREA Control Antibody (S), human IgG1
Hostcell line
Type of antibodyPrimary antibodies, Recombinant antibodies
Specieshuman
AntigenCD319 (CRACC)
Alternative names of antigenSLAMF7, 19A, CRACC, CS1
Molecular mass of antigen [kDa]35
Distribution of antigendendritic cells, NK cells
Entrez Gene ID57823
RRIDAB_2811326, AB_2657431, AB_2657432, AB_2811327

Resources for CD319 (CRACC) Antibody, anti-human, REAfinity™

Certificates

Please follow this
link
to search for Certificates of Analysis (CoA) by lot number.

References for CD319 (CRACC) Antibody, anti-human, REAfinity™

Publications

  1. Lee, J. K. et al. (2007) CS1 (CRACC, CD319) induces proliferation and autocrine cytokine expression on human B lymphocytes. J. Immunol. 179(7): 4672-4678
  2. Tassi, I. et al. (2005) The cytotoxicity receptor CRACC (CS-1) recruits EAT-2 and activates the PI3K and phospholipase C signaling pathways in human NK cells. J. Immunol. 175: 7996-8002
  3. Lee, J. K. et al. (2004) Molecular and functional characterization of a CS1 (CRACC) splice variant expressed in human NK cells that does not contain immunoreceptor tyrosine-based switch motifs. Eur. J. Immunol. 34(10): 2791-2799

Related products for
CD319 (CRACC) Antibody, anti-human, REAfinity™

2 products available

Seems like you are coming from USA!
Do you want to visit our website in your country?